NVCR

AcronymDefinition
NVCRNon-Violent Conflict Resolution
NVCRNorth Valley Cash Register (Red Bluff, CA)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Thus, nodes with higher NVCR and more residual energy are given higher probability to become active nodes:
* NovoCure (NASDAQ: NVCR) shares were up 1.86% on Friday morning to hit a new 52-week high of $91.24.
Novocure (NVCR) and Zai Lab (ZLAB) announced an exclusive license agreement for Tumor Treating Fields, including the brand name Optune, in Greater China and a global strategic development collaboration.
- Results from Jersey-based oncology company Novocure's (NASDAQ: NVCR) INNOVATE phase 2 pilot trial have been published in Gynecologic Oncology.
Helier, Jersey-based oncology company Novocure (NASDAQ: NVCR) has entered into a USD150 m term loan agreement with BioPharma Credit PLC (LSE: BPCR), an investment fund managed by Pharmakon Advisors, LP, with proceeds used to pay in full Novocure's existing USD 100m term loan debt and fund working capital, the company said.
- Physicians at 500 cancer treatment centers in the US have been certified to prescribe Jersey-based oncology company Novocure's (NASDAQ: NVCR) Optune to newly diagnosed and recurrent glioblastoma patients, the company said.
* NovoCure (NASDAQ: NVCR) shares were down 2.12% on Wednesday to hit a new 52-week high of $89.99 for a change of down 2.12%.
- The Japanese Ministry of Health, Labour and Welfare has approved Jersey-based oncology device company Novocure's (NASDAQ: NVCR) Optune (NovoTTF-100A) Tumor Treating Fields (TTFields) delivery system in the treatment of adult patients with supra-tentorial glioblastoma following maximal safe surgical resection and radiation therapy, the company said.
- The US Food and Drug Administration approved Jersey-based oncology company Novocure's (NASDAQ: NVCR) premarket approval supplement application for the second generation Optune system, the company said.
* NovoCure (NASDAQ: NVCR) shares were down 0.42% on Friday to hit a new 52-week high of $87.87 for a change of down 0.42%.
- The United States Food and Drug Administration has approved Jersey-based oncology company Novocure's (NASDAQ: NVCR) investigational device exemption application to initiate the METIS trial, the company said.
* NovoCure (NASDAQ: NVCR) shares broke to a new 52-week high of $86.66 on Thursday.